Cover Image
市場調查報告書

Sarepta Therapeutics, Inc.:開發中產品分析

Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 251769
出版日期 內容資訊 英文 73 Pages
訂單完成後即時交付
價格
Back to Top
Sarepta Therapeutics, Inc.:開發中產品分析 Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016
出版日期: 2016年07月13日 內容資訊: 英文 73 Pages
簡介

Sarepta Therapeutics, Inc. (舊AVI BioPharma, Inc.),是進行難治之症、感染疾病的治療用RNA治療藥的藥物研發、開發的生物醫藥品企業。在該公司,進行專門性、獨自性、創新性高的平台技術為基礎的藥物開發。現在該公司集中在裘馨氏肌肉萎縮症 (MDM) 的修飾藥的候補 (etepurirusen) 的開發,同時進行馬堡病毒出血熱病毒等感染疾病的治療藥候補的開發。

本報告提供美國的生物醫藥品企業,Sarepta Therapeutics, Inc. (Sarepta) 的醫藥品的研究開發進展相關分析、該公司的產品平台結構,及臨床實驗的整體進展、主要開發中產品簡介與開發情形、該公司簡介調查最新趨勢等。

Sarepta Therapeutics, Inc.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台、檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥

開發中產品的概要

  • 後期階段的開發中產品
    • 第三階段產品/並用治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段產品/並用治療模式
  • 初期階段的開發中產品
    • 取得IND/CTA認證的產品/並用治療模式
    • 臨床實驗前產品/並用治療模式
    • 藥物研發階段的產品/並用治療模式

藥物簡介

  • etepurirusen
    • 產品概要
    • 作用機制
    • 研究開發 (R&D) 的發展
  • SRP-4053
  • AVI-7288
  • radavirsen
  • SRP-4045
  • 洋蔥伯克霍爾德菌感染之AcpP抑制劑的反義寡核苷酸
  • DMD及Becker型MD的Myostatin抑制劑的反義寡核苷酸
  • PMO-25
  • SRP-4044
  • SRP-4050
  • SRP-4052
  • 鮑氏靜止桿菌感染疾病反之義寡核苷酸
  • 藥物抗性處於的淋病的反義寡核苷酸
  • 藥物抗性處於的綠色膿菌的反義寡核苷酸
  • 有甲氧西林抗性的黃色葡萄球菌的反義寡核苷酸
  • 難治之症的反義寡核苷酸
  • 早衰症之Lamin A活化劑的反義寡核苷酸
  • 龐貝氏症之α-Glucosidase活化劑的反義寡核苷酸
  • 肺炎桿菌之NDM-1抑制劑的反義寡核苷酸
  • 全身性紅斑性狼瘡 (SLE) 及移植物抗宿主病 (GVHD) 的TLR抑制劑的反義寡核苷酸
  • 感染疾病之反義寡核苷酸
  • 細菌性PPMO
  • SRP-4008
  • 病毒性PMO-X

開發平台分析

  • 各標靶
  • 各投藥法
  • 各分子類型
  • 各作用機制

開發中產品的最新趨勢

開發暫停的產品

開發中止的產品

  • 開發中止的產品簡介
    • AVI-4065
    • AVI-6002
    • AVI-7537

企業的聲明

公司所在地及子公司

  • 總公司
  • 其他的公司所在地、子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08091CDB

Summary

Global Markets Direct's, 'Sarepta Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the Sarepta Therapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Sarepta Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Sarepta Therapeutics, Inc.
  • The report provides overview of Sarepta Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Sarepta Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Sarepta Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Sarepta Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sarepta Therapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sarepta Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Sarepta Therapeutics, Inc. Snapshot
    • Sarepta Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Sarepta Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Sarepta Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Sarepta Therapeutics, Inc. - Pipeline Products Glance
    • Sarepta Therapeutics, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
    • Sarepta Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Sarepta Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Sarepta Therapeutics, Inc. - Drug Profiles
    • eteplirsen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRP-4053
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRP-4045
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AVI-7288
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • radavirsen
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit AcpP for Burkholderia Cepacia Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit Myostatin for DMD and Becker MD
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PMO-25
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRP-4008
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRP-4044
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRP-4050
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRP-4052
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SRP-4055
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide 1 to Activate Dystrophin for Duchenne Muscular Dystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide for Acinetobacter baumannii Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide for Drug Resistant Pseudomonas Aeruginosa Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide for Methicillin Resistant Staphylococcus Aureus Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Activate Dystrophin for Duchenne Muscular Dystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Activate Lamin A for Progeria
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Antisense Oligonucleotides for Infectious Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Bacterial PPMO
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Viral PMO-X
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Sarepta Therapeutics, Inc. - Pipeline Analysis
    • Sarepta Therapeutics, Inc. - Pipeline Products by Target
    • Sarepta Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Sarepta Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Sarepta Therapeutics, Inc. - Recent Pipeline Updates
  • Sarepta Therapeutics, Inc. - Dormant Projects
  • Sarepta Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • AVI-4065
      • AVI-6002
      • AVI-7537
  • Sarepta Therapeutics, Inc. - Company Statement
  • Sarepta Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Sarepta Therapeutics, Inc., Key Information
  • Sarepta Therapeutics, Inc., Key Facts
  • Sarepta Therapeutics, Inc. - Pipeline by Indication, 2016
  • Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Sarepta Therapeutics, Inc. - Pre-Registration, 2016
  • Sarepta Therapeutics, Inc. - Phase II, 2016
  • Sarepta Therapeutics, Inc. - Phase I, 2016
  • Sarepta Therapeutics, Inc. - Preclinical, 2016
  • Sarepta Therapeutics, Inc. - Discovery, 2016
  • Sarepta Therapeutics, Inc. - Pipeline by Target, 2016
  • Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • Sarepta Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Sarepta Therapeutics, Inc. - Recent Pipeline Updates, 2016
  • Sarepta Therapeutics, Inc. - Dormant Developmental Projects,2016
  • Sarepta Therapeutics, Inc. - Discontinued Pipeline Products, 2016
  • Sarepta Therapeutics, Inc., Other Locations
  • Sarepta Therapeutics, Inc., Subsidiaries

List of Figures

  • Sarepta Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
  • Sarepta Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • Sarepta Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • Sarepta Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
  • Sarepta Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • Sarepta Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • Sarepta Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top